Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Appelbaum

Showing results (101-110 of 490) with videos related to

Pageof 49
Sort By:
Cancer Treatment and Research|January 1, 1993
Radiolabeled antibody therapy of lymphomaO W Press, J Eary, F R Appelbaum, et al.
Leukemia|July 10, 1999
p73 mutations and expression in adult de novo acute myelogenous leukemiaD L Stirewalt, B Clurman, F R Appelbaum, et al.
Blood|May 23, 1998
Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine modelB M Sandmaier, R Storb, K L Bennett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2000
Second allogeneic transplantation after failure of first autologous transplantationJ P Radich, T Gooley, J E Sanders, et al.
Bone Marrow Transplantation|June 12, 2002
The use of radioimmunoconjugates in stem cell transplantationJ M Pagel, D C Matthews, F R Appelbaum, et al.
International Journal of Cell Cloning|January 1, 1986
Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantationK M Sullivan, F R Appelbaum, S J Horning, et al.
Cancer Treatment and Research|January 1, 1997
The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignanciesD C Matthews, F R Appelbaum, O W Press, et al.
Schweizerische Medizinische Wochenschrift|December 9, 1978
[Long-term, complete remission in non-Hodgkin's lymphoma following high-dosage combination therapy with or without autologous bone marrow transplantation]A A Gratwohl, F R Appelbaum, A S Levine, et al.
Current Opinion in Hematology|July 1, 1995
Targeted therapy for hematologic malignancies: has its promise been realized?D C Matthews, F R Appelbaum, O W Press, et al.
Leukemia Research|January 16, 2003
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpressionD L Stirewalt, F R Appelbaum, C L Willman, et al.
Pageof 49

Showing results (101-110 of 490) with videos related to

Sort By:
Pageof 49
Cancer Treatment and Research|January 1, 1993
Radiolabeled antibody therapy of lymphomaO W Press, J Eary, F R Appelbaum, et al.
Leukemia|July 10, 1999
p73 mutations and expression in adult de novo acute myelogenous leukemiaD L Stirewalt, B Clurman, F R Appelbaum, et al.
Blood|May 23, 1998
Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine modelB M Sandmaier, R Storb, K L Bennett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2000
Second allogeneic transplantation after failure of first autologous transplantationJ P Radich, T Gooley, J E Sanders, et al.
Bone Marrow Transplantation|June 12, 2002
The use of radioimmunoconjugates in stem cell transplantationJ M Pagel, D C Matthews, F R Appelbaum, et al.
International Journal of Cell Cloning|January 1, 1986
Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantationK M Sullivan, F R Appelbaum, S J Horning, et al.
Cancer Treatment and Research|January 1, 1997
The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignanciesD C Matthews, F R Appelbaum, O W Press, et al.
Schweizerische Medizinische Wochenschrift|December 9, 1978
[Long-term, complete remission in non-Hodgkin's lymphoma following high-dosage combination therapy with or without autologous bone marrow transplantation]A A Gratwohl, F R Appelbaum, A S Levine, et al.
Current Opinion in Hematology|July 1, 1995
Targeted therapy for hematologic malignancies: has its promise been realized?D C Matthews, F R Appelbaum, O W Press, et al.
Leukemia Research|January 16, 2003
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpressionD L Stirewalt, F R Appelbaum, C L Willman, et al.
Pageof 49